After BridgeBio Pharma announced “sustained positive results” from PROPEL 2, a Phase 2 trial of the investigational therapy infigratinib in children with achondroplasia, Wells Fargo said the 12- and 18-month data that show durable efficacy and clean safety “is a clear win” for BridgeBio. The data removes a key overhang and the HELIOS-B readout in late June or early July “may remove another one,” added the analyst, who has an Overweight rating and $58 price target on BridgeBio shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Announces Durable Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia, and First Participant Consented in ACCEL for Hypochondroplasia
- BridgeBio to Host Call on Month 12 and 18 Phase 2 Cohort 5 Results of Oral Infigratinib in Achondroplasia on June 4, 2024
- BridgeBio: Acoramidis data show boost in serum TTR levels in CV outcomes at ISA
- BridgeBio price target lowered to $47 from $51 at UBS
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
Questions or Comments about the article? Write to editor@tipranks.com